Leflunomide Aurovitas

Leflunomide, the active ingredient in Leflunomide Aurovitas, is a disease-modifying antirheumatic drug (DMARD) presented as an oral tablet for systemic use. It is indicated for the treatment of inflammatory arthritis in adult patients and reduces joint damage by inhibiting lymphocyte proliferation, often prescribed when conventional therapy is inadequate. The formulation complies with EU pharmaceutical regulations and is manufactured under GMP conditions.

GNH USA supplies Leflunomide Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent Good Distribution Practice (GDP) standards, ensuring product integrity during global shipment to hospitals, pharmacies and clinics across Europe, Asia, Africa and the Americas.

Leflunomide Aurovitas is a disease-modifying antirheumatic drug that targets immune-mediated inflammatory pathways in arthritis. - Rheumatoid arthritis: reduces joint inflammation, pain, and slows radiographic progression of structural damage. - Psoriatic arthritis: improves both skin lesions and joint symptoms, helping maintain functional ability and quality of life. - Moderate to severe inflammatory arthritis when other DMARDs are insufficient: offers an oral alternative that can achieve disease control and reduce flare frequency.

Leflunomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Diarrhea - Nausea or vomiting - Elevated liver enzymes - Hypertension

Serious or Rare Side Effects: - Severe liver injury or hepatitis - Life‑threatening infections - Pulmonary toxicity or interstitial lung disease - Stevens‑Johnson syndrome or toxic epidermal necrolysis

Before initiating Leflunomide therapy, several precautions and monitoring measures should be observed. - Pregnancy contraindication: avoid use in women of childbearing potential and discontinue immediately if pregnancy occurs. - Liver function monitoring: obtain baseline liver enzymes and repeat regularly during treatment. - Hematologic monitoring: perform complete blood counts to detect neutropenia or anemia. - Infection risk: assess for active infections and avoid initiating therapy in the presence of serious infection. - Hypertension monitoring: measure blood pressure periodically as the drug may raise systolic pressure. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Leflunomide can interact with several medicines, requiring dose adjustments or monitoring.

Major Interactions (Avoid): - Warfarin: may increase INR and bleeding risk. - Methotrexate: additive bone‑marrow suppression and hepatotoxicity. - Cholesterol‑binding resins (e.g., cholestyramine): markedly reduce leflunomide exposure.

Moderate Interactions (Monitor Closely): - CYP2C9 substrates (e.g., phenytoin, tolbutamide): may have altered plasma levels. - Statins: increased risk of myopathy when combined.